MicroStrategy’s Andrew Kang talks about bitcoin holdings, Krispy Kreme’s Jeremiah Ashukian discusses business model changes ...

Rivaling Eli Lilly’s (NYSE:LLY) direct-to-consumer platform LillyDirect, which made its market debut last year, Novo Nordisk ...

Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

The reductions come at a time of significant growth overall for Lilly. and soon after the announcement of plans to build new ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

Eli Lilly remains a favorite among billionaires, ranking 11th in top stock picks. The pharmaceutical giant’s 2024 revenue ...